Efficacy and safety of lanreotide autogel (LAN-ATG) 120 mg at extended dosing intervals (EDIs) in acromegalic patients biochemically controlled with octreotide LAR (OCT-LAR) 10 or 20 mg: The LEAD study

Authors :: Liudmila Rozhinskaya
Pascal Maisonobe
Monica R Gadelha
Caroline Sert
der Lelij Art-Jan van
Vyatcheslav Pronin
Inga Balcere
Moon-Kyu Lee
Marcello D. Bronstein
Source :: Endocrine Abstracts.
Publication Year :: 2014
Publisher :: Bioscientifica, 2014.

Subjects :: business.industry
Lanreotide Autogel
Medicine
Dosing
Pharmacology
business
Lead (electronics)
Octreotide lar

Full Text Access

Tools